The Netherlands Center for the Clinical advancement of Stem Cell and Gene Therapies (NECSTGEN), situated in Leiden, will comprise a state of the art GMP facility and expert knowledge for the development, production, and commercialization of cell and gene therapies.
NECSTGEN supports academic and small industrial therapy developers to translate research and early-stage clinical programs into actionable health solutions for patients. NECSTGEN will also support the development of therapeutics for orphan diseases that may be underserved but are nevertheless catastrophic to people who suffer from them.
NECSTGEN is a non-profit spin out of Leiden University Medical Center (LUMC) located in a purpose-built facility on the largest bio-cluster in the Netherlands, Leiden Bio Science Park (LBSP).
NECSTGEN builds further on the pioneering work in regenerative medicine by the LUMC. As spin-off dedicated to support the development and production of regenerative therapies, NECSTGEN aims to increase the development and GMP production capacity available for cell and gene therapies. To this end, NECSTGEN will identify and adopt the best international science, technology and practice. The facility is open to partners based worldwide, focusing on academic clients, hospital-based clinicians or start-up companies.
The facility will act as a hub to foster public-private interaction within the cell and gene therapy community, creating a network to link relevant stakeholders, therapy developers, service providers, government, regulators and investors.
Being situated in Leiden brings unique opportunities for NECSTGEN and its partners. Leiden Bio Science park is the 5th largest life science cluster in Europe. Leiden is a clinical, biotechnological, and pharmaceutical hub ideally positioned as a gateway to Europe and the world. Furthermore, the Leiden ecosystem complements the progression of therapy developers, providing greenfield sites for expansion, existing facilities to lease, contract research/manufacturing, relevant suppliers and logistics services locally.
The Netherlands, as a member of the EU, offers a uniquely open, business-friendly, stable and English-speaking environment, having additionally been chosen to host the European Medicines Agency (EMA) in Amsterdam. Amsterdam Schiphol airport is only 20 minutes from the LBSP and connects 327 international destinations directly (2018). The direct connections of Amsterdam Schiphol offer a clear logistical advantage to therapy developers when thinking about complex supply chains, patient material and therapy shipment.